Understanding what makes COVID-19 more infectious than SARS

Australian and International researchers continue to have rapid access to the macromolecular and microfocus beamlines at the Australian Synchrotron to solve protein structures in the fight against COVID-19.

“Since coming out of a hard lockdown, we are now accepting proposals for other research,” said Principal Scientist Dr Alan Riboldi-Tunnicliffe.

“Because scientists can access the beamline remotely, they do not have to worry about changes to borders and travel restrictions.”

There have been a number of COVID-19 publications, which included structural information about key proteins in the virus, from the beamlines.

Instrument scientist Dr Eleanor Campbell reports that an international team of researchers led by the University of Bristol (UK) have identified a possible cause of SARS-CoV-2’s increased infectivity compared to SARS-CoV (the virus which emerged in China in 2003) , which could provide a target for developing COVID-19 therapies.

Australian collaborators included researchers from the Institute of Molecular Bioscience at the University of Queensland, who sent the samples to the Australian Synchrotron.

Read more on the Australian Synchrotron website

Scientists discover potential method to starve the bacteria that cause Tuberculosis

By deepening our understanding of how Tuberculosis bacteria feed themselves, University of Guelph researchers have identified a potential target for drug treatment. The team used the Canadian Light Source (CLS) at the University of Saskatchewan to image the bacteria in fine detail.

The infectious disease Tuberculosis (TB) is one of the leading causes of death worldwide. While rates of TB in Canada have remained relatively static since the 1980s, the disease disproportionately affects Indigenous populations. With TB-causing bacteria becoming increasingly resistant to antibiotics, researchers and drug makers are eager to find new, more effective treatments.

Researchers have known for some time that the bacteria that causes TB (Mycobacterium tuberculosis) uses our body’s cholesterol – a steroid – as a food source. Other relatives of the bacteria that do not cause disease share its ability to break down steroids. In this study, the University of Guelph team identified the structure of an enzyme (acyl CoA dehydrogenase) involved in steroid degradation in another member of the same bacteria family, called Thermomonospora curvata.

Read more on the CLS Website

Image: This rendering shows the shape of a tunnel (orange) where the substrate binds. Any drugs targeting this enzyme would need to fit to this pocket.

“foot-2-foot” interaction sheds light on bacterial conjugation

Bacteria possess mechanisms to establish communication between cells. This is especially important in bacterial conjugation, a process that allows bacteria to share genetic material. This is often used by bacteria to transfer antibiotic resistance genes and other virulence factors to neighbor cells, increasing the antibiotic resistance spread.

Now, a research team of ALBA scientists report the structural mechanism by which two proteins, Rap and Rco, act together to regulate conjugation. Rco is a repressor of conjugation, whereas Rap binds Rco and prevents Rco-mediated conjugation repression, thus resulting in an activation of the conjugation mechanism. The main results of the study show that Rap contains a binding pocket were a short peptide can bind, producing structural changes in Rap that forces its tetramerization, releasing Rco for blocking conjugation. Tetramerization occurs through an interaction that scientists named “foot-2-foot”, which differs significantly from the model proposed for other proteins of the Rap family.

Read more on the ALBA website

Image: RappLS20 tetramerization, side view of the peptide-bound tetramer. The red arrows indicate the loops connecting helices H4 and H5. (C) Zoom of the area around the N-terminus of helix H4, showing the insertion of this helix into the opposite monomer. The homotetramerization caused by the foot-2-foot interactions of the NTDs of RappLS20 provides an explanation for the activation of the RcopLS20 partner. In the absence of the peptide, the NTDs are positioned such that they allow the interaction with RcopLS20. However, upon binding the signaling peptide, the NTDs shift outwards, facilitating the formation of the homotetramer, leading to a change of the interaction surface of the NTDs that is no longer available for interactions with RcopLS20

Effective new target for breast cancer treatment

An international study led by scientists at the University of Sussex has provided strong evidence for an effective new target for breast cancer treatment. The five-year study, called “The structure-function relationship of oncogenic LMTK3” published in Science Advances, involved researchers from seven institutions across three countries including Diamond. 

The study suggests that LMTK3 inhibitors could be effectively used for the treatment of breast cancer, and potentially other types of cancer. The structure of oncogenic LMTK3 (Lemur Tyrosine Kinase 3 ) determines its role and functions allowing drug inhibition as a new therapeutic strategy.

It is hoped the research will allow the further development and optimisation of LMTK3 inhibitors as a new type of orally-administered anticancer drug for patients and have potential value not only for breast cancer patients but also for lung, stomach, thyroid and bladder cancer patients.

Read more on the Diamond Light Source website

Image: Crystal structure of LMTK3
Credit: University of Sussex